The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2007
year mood +0.21 · -0.12 to +0.30 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan +0.30 Feb Mar Apr May -0.12 Jun Jul Aug Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.30+0.30+0.30+0.30-0.12+0.20+0.30+0.20+0.20+0.30-0.09+0.30

Steady in the bull-market peak, though the 'patent cliff' narrative loomed and GSK's Avandia safety scare hit in May; Merck's $4.85B Vioxx settlement in November finally removed a huge liability overhang.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2007
May
Avandia linked to 43% higher heart attack risk, FDA warns cleveland19.com →

A new analysis links GlaxoSmithKline's diabetes drug Avandia to a 43% higher risk of heart attack, prompting an FDA safety alert but no immediate regulatory action. The revelation sparked congressional concern, eroded investor confidence—sending GSK shares down 6.6%—and reignited criticism of FDA's drug approval and safety monitoring processes.

Nov
Merck to Pay $4.85B to Settle Vioxx Lawsuits npr.org →

Merck & Co. agreed to a $4.85 billion settlement to resolve around 47,000 lawsuits linked to its withdrawn painkiller Vioxx, which was tied to increased heart attack and stroke risks. The deal, excluding class-action admissions, establishes separate funds for qualifying myocardial infarction and stroke claims, with Merck taking a full charge in Q4; the stock rose on investor relief over litigation certainty.